PL371594A1 - Zmodyfikowany wirus krowianki Ankara do szczepienia noworodków - Google Patents

Zmodyfikowany wirus krowianki Ankara do szczepienia noworodków

Info

Publication number: PL371594A1
Authority: PL; Poland
Prior art keywords: virus; vaccination; antigens; neonatal; human
Prior art date: 2002-04-19

Application number

PL03371594A

Other languages

English (en)

Other versions

PL220781B1 (pl

Inventor

Paul Chaplin

Mark Suter

Mathias Ackermann

Marco Franchini

Sabine Vollstedt

Hans Peter Hefti

Original Assignee

Bavarian Nordic A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-19

Filing date

2003-04-16

Publication date

2005-06-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-04-16 Application filed by Bavarian Nordic A/S filed Critical Bavarian Nordic A/S

2005-06-27 Publication of PL371594A1 publication Critical patent/PL371594A1/pl

2016-01-29 Publication of PL220781B1 publication Critical patent/PL220781B1/pl

Links

238000002255 vaccination Methods 0.000 title abstract 5
241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 2
241000700605 Viruses Species 0.000 abstract 9
239000000427 antigen Substances 0.000 abstract 6
102000036639 antigens Human genes 0.000 abstract 6
108091007433 antigens Proteins 0.000 abstract 6
241001465754 Metazoa Species 0.000 abstract 3
210000004027 cell Anatomy 0.000 abstract 3
102000014150 Interferons Human genes 0.000 abstract 2
108010050904 Interferons Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
210000004443 dendritic cell Anatomy 0.000 abstract 2
208000015181 infectious disease Diseases 0.000 abstract 2
229940079322 interferon Drugs 0.000 abstract 2
239000002243 precursor Substances 0.000 abstract 2
230000001413 cellular effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL371594A 2002-04-19 2003-04-16 Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN PL220781B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DKPA200200590		2002-04-19

Publications (2)

Publication Number	Publication Date
PL371594A1 true PL371594A1 (pl)	2005-06-27
PL220781B1 PL220781B1 (pl)	2016-01-29

Family

ID=29225556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371594A PL220781B1 (pl)	2002-04-19	2003-04-16	Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN

Country Status (23)

Country	Link
US (3)	US7897156B2 (pl)
EP (4)	EP1420822B2 (pl)
JP (4)	JP4801880B2 (pl)
KR (2)	KR101028937B1 (pl)
CN (1)	CN100540051C (pl)
AT (1)	ATE366586T2 (pl)
AU (1)	AU2003239805B2 (pl)
BR (1)	BR0309339A (pl)
CA (1)	CA2478009C (pl)
CY (1)	CY1106848T1 (pl)
DE (1)	DE60314823T3 (pl)
DK (1)	DK1420822T4 (pl)
EA (1)	EA011233B1 (pl)
ES (1)	ES2288609T5 (pl)
IL (1)	IL163701A0 (pl)
MX (1)	MXPA04010353A (pl)
NO (1)	NO336348B1 (pl)
NZ (2)	NZ547776A (pl)
PL (1)	PL220781B1 (pl)
PT (1)	PT1420822E (pl)
SG (1)	SG173216A1 (pl)
UA (1)	UA85371C2 (pl)
WO (1)	WO2003088994A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7628980B2 (en) *	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
WO2002042480A2 (en) *	2000-11-23	2002-05-30	Bavarian Nordic A/S	Modified vaccinia ankara virus variant
EP1420822B2 (en) *	2002-04-19	2017-07-05	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
WO2004043490A1 (en) *	2002-11-07	2004-05-27	Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health	Smallpox vaccine regimen
BRPI0608310A2 (pt)	2005-02-23	2009-12-08	Bavarian Nordic As	uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos
EP1835031A1 (en) *	2006-03-14	2007-09-19	Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe	Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) *	2007-04-27	2012-09-18	Bavarian Nordic A/S	Immediate protection against pathogens via MVA
US20110052627A1 (en) *	2008-06-20	2011-03-03	Paul Chaplin	Recombinant modified vaccinia virus measles vaccine
US8883168B2 (en)	2010-11-05	2014-11-11	Bavarian Nordic A/S	Modulation of immune responses by the poxviral K4 protein
JP6309274B2 (ja) *	2011-03-11	2018-04-11	ターンストーン・リミテッド・パートナーシップ	ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
EP2892549A1 (en) *	2012-09-04	2015-07-15	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
WO2014139687A1 (en) *	2013-03-15	2014-09-18	Bavarian Nordic A/S	Single high dose of mva induces a protective immune response in neonates and infants
US10801070B2 (en)	2013-11-25	2020-10-13	The Broad Institute, Inc.	Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en)	2013-12-05	2015-06-11	The Broad Institute Inc.	Polymorphic gene typing and somatic change detection using sequencing data
CN120695169A (zh)	2013-12-20	2025-09-26	博德研究所	使用新抗原疫苗的联合疗法
WO2016100977A1 (en)	2014-12-19	2016-06-23	The Broad Institute Inc.	Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en)	2014-12-19	2016-06-23	Massachsetts Institute Ot Technology	Molecular biomarkers for cancer immunotherapy
UA113442C2 (xx)	2015-01-27	2017-01-25		Ентеросорбент
BR112017018160A2 (pt) *	2015-02-25	2018-04-10	Memorial Sloan-Kettering Cancer Center	uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
CN107847534B (zh)	2015-04-17	2022-10-04	纪念斯隆凯特琳癌症中心	Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
EP3297660A2 (en)	2015-05-20	2018-03-28	The Broad Institute Inc.	Shared neoantigens
TWI750122B (zh)	2015-06-09	2021-12-21	美商博德研究所有限公司	用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr)	2015-10-08	2017-04-14	Jean-Marc Limacher	Composition anti-tumorale
US10736962B2 (en)	2016-02-25	2020-08-11	Memorial Sloan Kettering Cancer Center	Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
CN116440176A (zh)	2016-02-25	2023-07-18	纪念斯隆凯特琳癌症中心	具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
US20190346442A1 (en)	2016-04-18	2019-11-14	The Broad Institute, Inc.	Improved hla epitope prediction
US11549149B2 (en)	2017-01-24	2023-01-10	The Broad Institute, Inc.	Compositions and methods for detecting a mutant variant of a polynucleotide
CN111107872A (zh)	2017-05-12	2020-05-05	纪念斯隆-凯特林癌症中心	有用于癌症免疫疗法的牛痘病毒突变体
BR112021004692A2 (pt)	2018-09-15	2021-06-08	Memorial Sloan Kettering Cancer Center	poxvírus recombinantes para imunoterapia de câncer
US20210382068A1 (en)	2018-10-02	2021-12-09	Dana-Farber Cancer Institute, Inc.	Hla single allele lines
US20220062394A1 (en)	2018-12-17	2022-03-03	The Broad Institute, Inc.	Methods for identifying neoantigens
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
US12394502B2 (en)	2019-10-02	2025-08-19	The General Hospital Corporation	Method for predicting HLA-binding peptides using protein structural features
CR20220220A (es)	2019-11-18	2022-09-20	Janssen Biotech Inc	Vacunas basadas en calr y jak2 mutantes y sus usos
US12295997B2 (en)	2020-07-06	2025-05-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
EP4452305A1 (en) *	2021-12-23	2024-10-30	Bavarian Nordic A/S	Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en)	2022-07-13	2024-01-18	The Broad Institute, Inc.	Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) *	2023-05-31	2026-01-20	Northeastern University	Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) *	2023-11-07	2026-02-24	New York University	Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
FR3160186A1 (fr)	2024-03-13	2025-09-19	Odimma Therapeutics	Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3914408A (en) *	1973-10-12	1975-10-21	Univ Nebraska	Vaccine for neonatal calf diarrhea
DE2714665A1 (de) *	1977-04-01	1978-10-05	Mayr Anton	Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) †	1983-08-09	1985-02-23	Nippon Denso Co Ltd	アンチスキツド制御装置
US6248333B1 (en) *	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) *	1991-03-07	1998-12-01	Virogenetics Corporation	Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) *	1993-01-21	1995-04-04	Nippon Zeon Co., Ltd.	Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) *	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
US6190655B1 (en) *	1993-12-03	2001-02-20	Immunex Corporation	Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) *	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2243937T3 (es) *	1994-04-29	2005-12-01	Baxter Healthcare S.A.	Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US5756341A (en) *	1994-11-10	1998-05-26	Immuno Ag	Method for controlling the infectivity of viruses
US5753489A (en) *	1994-11-10	1998-05-19	Immuno Ag	Method for producing viruses and vaccines in serum-free culture
UA68327C2 (en) *	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EA002020B1 (ru)	1996-02-21	2001-12-24	Джулианна Лисцивич	Способ генерации противовирусного иммунного ответа у человека или животного
WO1998013500A2 (en) *	1996-09-24	1998-04-02	Bavarian Nordic Research Institute A/S	Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) *	1996-10-25	1998-04-30	The Wistar Institute Of Anatomy & Biology	Method of vaccinating infants against infections
US6204250B1 (en) *	1996-11-22	2001-03-20	The Mount Sinai Medical Center Of The City Of New York	Immunization of infants
GB9711957D0 (en) †	1997-06-09	1997-08-06	Isis Innovation	Methods and reagents for vaccination
GB0023203D0 (en) *	2000-09-21	2000-11-01	Isis Innovation	Vaccination method
WO1999007869A1 (en)	1997-08-05	1999-02-18	University Of Florida	Live recombinant vaccine comprising inefficiently or non-replicating virus
GB2370573A (en)	1998-11-18	2002-07-03	Oxford Biomedica Ltd	Poxviral vectors
EP1036091B2 (en)	1998-11-18	2008-03-26	Oxford Biomedica (UK) Limited	5t4 tumour-associated antigen for use in tumour immunotherapy
CN1291012C (zh) *	2000-03-14	2006-12-20	巴法里安诺迪克有限公司	修饰的安卡拉牛痘病毒(mva)的变株
JP2003533989A (ja)	2000-05-24	2003-11-18	メリアル	ブタ生殖・呼吸症候群ウィルス（ｐｒｒｓｖ）の組換えポックスウィルスワクチン
JP2004507231A (ja) *	2000-06-15	2004-03-11	アメリカ合衆国	免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用
NZ523534A (en) *	2000-07-11	2005-02-25	Bayer Ag	Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
DE10042598A1 (de) *	2000-08-30	2002-03-28	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
WO2002042480A2 (en) *	2000-11-23	2002-05-30	Bavarian Nordic A/S	Modified vaccinia ankara virus variant
US7445924B2 (en) *	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en) *	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) *	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US20040091995A1 (en) *	2001-06-15	2004-05-13	Jeffrey Schlom	Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
EP2345665A3 (en) *	2001-12-04	2012-02-15	Bavarian Nordic A/S	Flavivirus NS1 subunit vaccine
EP1420822B2 (en) *	2002-04-19	2017-07-05	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
NZ536501A (en) *	2002-05-16	2006-08-31	Bavarian Nordic As	Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
BRPI0414224A (pt) *	2003-09-10	2006-12-26	Ra Brands Llc	método de acabamento de uma nervura para uma arma de fogo
US8933041B2 (en) *	2003-11-12	2015-01-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	System for treating and preventing breast cancer
US7618980B2 (en) *	2004-07-14	2009-11-17	Bristol-Myers Squibb Company	Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en)	2006-03-14	2007-09-19	Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe	Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en)	2006-11-20	2008-05-28	Paul-Ehrlich-Institut	Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) *	2009-03-13	2013-12-24	Bavarian Nordic A/S	Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

2003
- 2003-04-16 EP EP03732280.7A patent/EP1420822B2/en not_active Expired - Lifetime
- 2003-04-16 SG SG2007001563A patent/SG173216A1/en unknown
- 2003-04-16 EP EP10158054A patent/EP2204180A3/en not_active Withdrawn
- 2003-04-16 CN CNB038087863A patent/CN100540051C/zh not_active Expired - Lifetime
- 2003-04-16 DK DK03732280.7T patent/DK1420822T4/en active
- 2003-04-16 UA UA20041008381A patent/UA85371C2/ru unknown
- 2003-04-16 PT PT03732280T patent/PT1420822E/pt unknown
- 2003-04-16 EA EA200401405A patent/EA011233B1/ru not_active IP Right Cessation
- 2003-04-16 EP EP07013067A patent/EP1839672A3/en not_active Withdrawn
- 2003-04-16 BR BR0309339-5A patent/BR0309339A/pt not_active Application Discontinuation
- 2003-04-16 AU AU2003239805A patent/AU2003239805B2/en not_active Expired
- 2003-04-16 CA CA2478009A patent/CA2478009C/en not_active Expired - Lifetime
- 2003-04-16 KR KR1020047015645A patent/KR101028937B1/ko not_active Expired - Lifetime
- 2003-04-16 KR KR1020117000242A patent/KR20110017904A/ko not_active Ceased
- 2003-04-16 PL PL371594A patent/PL220781B1/pl unknown
- 2003-04-16 JP JP2003585745A patent/JP4801880B2/ja not_active Expired - Lifetime
- 2003-04-16 IL IL16370103A patent/IL163701A0/xx unknown
- 2003-04-16 AT AT03732280T patent/ATE366586T2/de active
- 2003-04-16 DE DE60314823.9T patent/DE60314823T3/de not_active Expired - Lifetime
- 2003-04-16 EP EP10158052A patent/EP2204179A3/en not_active Withdrawn
- 2003-04-16 NZ NZ547776A patent/NZ547776A/xx not_active IP Right Cessation
- 2003-04-16 NZ NZ536592A patent/NZ536592A/en not_active IP Right Cessation
- 2003-04-16 ES ES03732280.7T patent/ES2288609T5/es not_active Expired - Lifetime
- 2003-04-16 WO PCT/EP2003/003994 patent/WO2003088994A2/en not_active Ceased
- 2003-04-16 MX MXPA04010353A patent/MXPA04010353A/es active IP Right Grant
2004
- 2004-11-12 NO NO20044941A patent/NO336348B1/no not_active IP Right Cessation
2007
- 2007-09-07 CY CY20071101154T patent/CY1106848T1/el unknown
2008
- 2008-05-12 US US12/118,841 patent/US7897156B2/en not_active Expired - Fee Related
2010
- 2010-02-12 JP JP2010028940A patent/JP2010120955A/ja active Pending
2011
- 2011-01-19 US US13/009,636 patent/US8163293B2/en not_active Expired - Fee Related
- 2011-05-24 JP JP2011115564A patent/JP5690214B2/ja not_active Expired - Lifetime
2012
- 2012-03-16 US US13/422,028 patent/US20120183574A1/en not_active Abandoned
2014
- 2014-12-19 JP JP2014257263A patent/JP2015061876A/ja active Pending

Also Published As

Publication number	Publication date
WO2003088994A3 (en)	2004-02-19
PL220781B1 (pl)	2016-01-29
DE60314823T2 (de)	2008-03-13
CA2478009C (en)	2019-03-26
EP1420822B1 (en)	2007-07-11
UA85371C2 (ru)	2009-01-26
EP1420822A2 (en)	2004-05-26
CN1646158A (zh)	2005-07-27
EA200401405A1 (ru)	2005-04-28
PT1420822E (pt)	2007-09-04
JP2015061876A (ja)	2015-04-02
MXPA04010353A (es)	2005-03-07
JP2011157400A (ja)	2011-08-18
SG173216A1 (en)	2011-08-29
EP1839672A3 (en)	2007-11-21
EA011233B1 (ru)	2009-02-27
US7897156B2 (en)	2011-03-01
EP2204180A3 (en)	2010-12-22
ES2288609T5 (es)	2017-11-13
DK1420822T4 (en)	2017-10-09
EP2204180A2 (en)	2010-07-07
WO2003088994A2 (en)	2003-10-30
DK1420822T3 (da)	2007-10-08
NZ536592A (en)	2007-01-26
KR20110017904A (ko)	2011-02-22
US8163293B2 (en)	2012-04-24
HK1078777A1 (zh)	2006-03-24
JP2010120955A (ja)	2010-06-03
JP2005523318A (ja)	2005-08-04
AU2003239805B2 (en)	2009-09-10
NO20044941L (no)	2004-11-12
EP1839672A2 (en)	2007-10-03
CA2478009A1 (en)	2003-10-30
US20120183574A1 (en)	2012-07-19
US20110135683A1 (en)	2011-06-09
EP1420822B2 (en)	2017-07-05
NZ547776A (en)	2009-08-28
IL163701A0 (en)	2005-12-18
BR0309339A (pt)	2005-03-08
EP2204179A2 (en)	2010-07-07
US20090104224A1 (en)	2009-04-23
JP4801880B2 (ja)	2011-10-26
CY1106848T1 (el)	2012-05-23
DE60314823T3 (de)	2017-11-16
JP5690214B2 (ja)	2015-03-25
DE60314823D1 (de)	2007-08-23
ES2288609T3 (es)	2008-01-16
ATE366586T2 (de)	2007-08-15
KR101028937B1 (ko)	2011-04-12
CN100540051C (zh)	2009-09-16
EP2204179A3 (en)	2010-12-22
KR20040111467A (ko)	2004-12-31
NO336348B1 (no)	2015-08-03
AU2003239805A1 (en)	2003-11-03

Publication	Publication Date	Title
IL163701A0 (en)	2005-12-18	Modified vaccinia virus ankara for the vaccinationof neonates
Bode et al.	1996	First isolates of infectious human Borna disease virus from patients with mood disorders
Gherardi et al.	2003	IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system
HK1052725B (zh)	2007-03-23	修饰的安卡拉牛痘病毒(mva)的变株
Lin et al.	2005	The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs
DE60043624D1 (de)	2010-02-11	DNA-Impfung zur Behandlung von Autoimmunerkrankungen
KR102451441B1 (ko)	2022-10-12	신규 면역증강제 및 이를 포함하는 백신 조성물
CA2501220A1 (en)	2004-05-21	Vaccines against west nile virus
US20170335345A1 (en)	2017-11-23	Pharmaceutical composition for treatment and/or prevention of hepatitis c
KR100790801B1 (ko)	2008-01-04	동물용 불활화 백신의 제조방법
WO2002081712A3 (en)	2003-10-02	Artificial chromosomes comprising ehv sequences
Wang et al.	2018	Construction, identification, and immunogenic assessments of an HSV-1 mutant vaccine with a UL18 deletion
CN110923248B (zh)	2021-09-17	猪繁殖与呼吸综合征病毒、疫苗及其制备方法和用途
WO2024049355A1 (en)	2024-03-07	Mutations that stabilize and attenuate dengue virus genome
KR20250140913A (ko)	2025-09-26	병원성이 약화된 아프리카돼지열병 바이러스 및 이를 포함하는 아프리카돼지열병 예방용 백신 조성물
KR20230144464A (ko)	2023-10-16	신규한 재조합 돼지 생식기 호흡기 증후군 바이러스주 kprrsv2-d4
KR20150137215A (ko)	2015-12-09	신규한 돼지 생식기 호흡기 증후군 바이러스, prrs 예방 또는 치료용 면역원성 조성물, 및 그를 이용하여 prrs를 예방 또는 치료하는 방법
HK1078777B (en)	2010-01-22	Modified vaccinia virus ankara for the vaccination of neonates
TH62970A (th)	2004-07-19	วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)
TH60798A (th)	2004-02-13	ชีวมวลที่เป็นอนุภาคเอมบริโอของสัตว์ปีกสำหรับการผลิตแอนติเจนของไวรัส